Cargando…

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples

SIMPLE SUMMARY: Prostate cancer (PCa) is the most prevalent cancer in males worldwide, and it was the fifth leading cause of cancer mortality in this group in 2020. Near 70% of advanced-stage PCa patients will undergo bone metastasis, suffering pathological complications that severely affect patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olivan, Mireia, Garcia, Marta, Suárez, Leticia, Guiu, Marc, Gros, Laura, Méndez, Olga, Rigau, Marina, Reventós, Jaume, Segura, Miguel F., de Torres, Inés, Planas, Jacques, de la Cruz, Xavier, Gomis, Roger R., Morote, Juan, Rodríguez-Barrueco, Ruth, Santamaria, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699528/ https://www.ncbi.nlm.nih.gov/pubmed/34944822 http://dx.doi.org/10.3390/cancers13246202

Ejemplares similares

Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness
por: Morote, Juan, et al.
Publicado: (2014)

The Present and Future of Prostate Cancer Urine Biomarkers
por: Rigau, Marina, et al.
Publicado: (2013)

Molecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues
por: Sequeiros, Tamara, et al.
Publicado: (2013)

Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines
por: Olivan, M., et al.
Publicado: (2015)

Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer
por: Sequeiros, Tamara, et al.
Publicado: (2016)

Identification, characterization and expression of novel Sex Hormone Binding Globulin alternative first exons in the human prostate
por: Pinós, Tomàs, et al.
Publicado: (2009)

Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells
por: Cánovas, Verónica, et al.
Publicado: (2017)

The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category
por: Morote, Juan, et al.
Publicado: (2022)

Definition of Castrate Resistant Prostate Cancer: New Insights
por: Morote, Juan, et al.
Publicado: (2022)

Estrogen Receptor Beta Displays Cell Cycle-Dependent Expression and Regulates the G1 Phase through a Non-Genomic Mechanism in Prostate Carcinoma Cells
por: Hurtado, Antoni, et al.
Publicado: (2008)

Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
por: Campistol, Miriam, et al.
Publicado: (2022)

Low-dose statin treatment increases prostate cancer aggressiveness
por: Caro-Maldonado, Alfredo, et al.
Publicado: (2017)

Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review
por: Cuadras, Mercè, et al.
Publicado: (2022)

A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand
por: Morote, Juan, et al.
Publicado: (2022)

A risk‐organised model for clinically significant prostate cancer early detection
por: Morote, Juan, et al.
Publicado: (2023)

Non-Coding RNAs in Saliva: Emerging Biomarkers for Molecular Diagnostics
por: Majem, Blanca, et al.
Publicado: (2015)

The Barcelona Predictive Model of Clinically Significant Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients
por: Morote, Juan, et al.
Publicado: (2017)

Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy
por: Morote, Juan, et al.
Publicado: (2022)

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2023)

Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review
por: Triquell, Marina, et al.
Publicado: (2022)

Association of prostate volume with incidence and aggressiveness of prostate cancer
por: Al-Khalil, Shadi, et al.
Publicado: (2016)

E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness
por: Rosso, Marina, et al.
Publicado: (2017)

Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer
por: Puig, Pere, et al.
Publicado: (2019)

Multiparametric MRI for Staging of Prostate Cancer: A Multicentric Analysis of Predictive Factors to Improve Identification of Extracapsular Extension before Radical Prostatectomy
por: Triquell, Marina, et al.
Publicado: (2022)

Prostate Cancer Aggressiveness Prediction Using CT Images
por: Mendes, Bruno, et al.
Publicado: (2021)

Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate Cancer
por: Barber, Alison G., et al.
Publicado: (2014)

Human SHBG mRNA Translation Is Modulated by Alternative 5′-Non-Coding Exons 1A and 1B
por: Pinós, Tomàs, et al.
Publicado: (2010)

Exosome-like vesicles in uterine aspirates: a comparison of ultracentrifugation-based isolation protocols
por: Campoy, Irene, et al.
Publicado: (2016)

Neuroendocrine and Aggressive-Variant Prostate Cancer
por: Spetsieris, Nicholas, et al.
Publicado: (2020)

Biomarkers of Aggressive Prostate Cancer at Diagnosis
por: Boehm, Brock E., et al.
Publicado: (2023)

Intraductal prostate cancer: An aggressive subset of prostate cancers? Immunophenotypic evaluation
por: Faviana, Pinuccia, et al.
Publicado: (2022)

Prostate cancer aggressiveness and financial toxicity among prostate cancer patients
por: KC, Madhav, et al.
Publicado: (2022)

Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers
por: Li, Qing Kay, et al.
Publicado: (2015)

Characterisation of the main PSA glycoforms in aggressive prostate cancer
por: Gratacós-Mulleras, Anna, et al.
Publicado: (2020)

Stratifying the initial prostate cancer suspicion to avoid magnetic resonance exams by sequencing men according to serum prostate‐specific antigen, digital rectal examination and the prostate‐specific antigen density based on digital rectal prostate volume category
por: Morote, Juan, et al.
Publicado: (2022)

The role of prostate tumor overexpressed 1 in cancer progression
por: Cánovas, Verónica, et al.
Publicado: (2016)

Serum Luteinizing Hormone Testing Can Identify Optimal Medical Castration
por: Morote, Juan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ecspcn639mkq8db5mdk0lnf1ok